Skip to Content

New Additions to Drugs.com for 2017

We update the Drugs.com database on a regular cycle. The following new drug information has been added this year:

Showing additions for:

Ozempic
Dec 6, 2017 - Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the treatment of adults with type 2 diabetes.

Juluca
Nov 23, 2017 - Juluca (dolutegravir and rilpivirine) is a single-tablet, two-drug regimen of the approved drugs dolutegravir (Tivicay) and rilpivirine (Edurant) for the maintenance treatment of virologically suppressed HIV-1 infection.

Hemlibra
Nov 23, 2017 - Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody indicated to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.

Prevymis
Nov 22, 2017 - Prevymis (letermovir) a CMV DNA terminase complex inhibitor indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult allogeneic hematopoietic stem cell transplant patients.

Fasenra
Nov 15, 2017 - Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the treatment of patients with severe eosinophilic asthma.

Calquence
Oct 31, 2017 - Calquence (acalabrutinib) is a highly selective, potent, Bruton tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL).

Yescarta
Oct 19, 2017 - Yescarta (axicabtagene ciloleucel) is a chimeric antigen receptor T cell (CAR T) therapy for the treatment of adults patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Verzenio
Oct 1, 2017 - Verzenio (abemaciclib) is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 for the treatment of metastatic breast cancer.

Trelegy Ellipta
Sep 27, 2017 - Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is an inhaled corticosteroid, long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) combination for the treatment of patients with chronic obstructive pulmonary disease (COPD).

Solosec
Sep 26, 2017 - Solosec (secnidazole) is a nitroimidazole antimicrobial for use as a single-dose oral therapy in the treatment of bacterial vaginosis (BV).

Aliqopa
Sep 17, 2017 - Aliqopa (copanlisib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma.

benznidazole
Aug 31, 2017 - Benznidazole is an antiprotozoal indicated for the treatment of Chagas disease, or American trypanosomiasis, a parasitic infection caused by Trypanosoma cruzi.

Kymriah
Aug 30, 2017 - Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy for use in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL).

Duzallo
Aug 21, 2017 - Duzallo (allopurinol and lesinurad) is a xanthine oxidase inhibitor and URAT1 inhibitor fixed-dose combination for the treatment of hyperuricemia in patients with uncontrolled gout.

Mavyret
Aug 6, 2017 - Mavyret (glecaprevir/pibrentasvir) is a fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, indicated for the treatment of all major genotypes (GT1-6) of chronic hepatitis C.

Idhifa
Aug 1, 2017 - Idhifa (enasidenib) is a first-in-class, oral, targeted inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation.

Vosevi
Jul 19, 2017 - Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a single-tablet regimen for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1-6.

Nerlynx
Jul 17, 2017 - Nerlynx (neratinib) is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with early stage HER2-positive breast cancer.

Tremfya
Jul 17, 2017 - Tremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Bevyxxa
Jun 26, 2017 - Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at risk adult patients hospitalized for an acute medical illness.

Rituxan Hycela
Jun 26, 2017 - Rituxan Hycela (rituximab and hyaluronidase human) is a subcutaneous monoclonal antibody and hyaluronidase human formulation for the treatment of adult patients with follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

Baxdela
Jun 19, 2017 - Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

Imfinzi
May 29, 2017 - Imfinzi (durvalumab) is an anti-PD-L1 (programmed death ligand-1) human monoclonal antibody for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Radicava
May 29, 2017 - Radicava (edaravone) is a free radical scavenger that relieves the effects of oxidative stress, a likely factor in the onset and progression of amyotrophic lateral sclerosis.

Kevzara
May 24, 2017 - Kevzara (sarilumab) is an interleukin-6 receptor (IL-6R) antibody for the treatment of adults with rheumatoid arthritis.

Tymlos
May 10, 2017 - Tymlos (abaloparatide) is a synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein) for the treatment of postmenopausal women with osteoporosis.

Rydapt
May 9, 2017 - Rydapt (midostaurin) is an oral, multi-targeted kinase inhibitor for the treatment of acute myeloid leukemia (AML) in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, and for the treatment of advanced systemic mastocytosis (SM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) and mast cell leukemia.

Alunbrig
May 6, 2017 - Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell cancer (NSCLC) whose disease is resistant to crizotinib.

Ingrezza
Apr 12, 2017 - Ingrezza (valbenazine) is a novel, highly-selective VMAT2 inhibitor for the treatment of tardive dyskinesia.

Austedo
Apr 3, 2017 - Austedo (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease and the treatment of tardive dyskinesia.

Ocrevus
Mar 29, 2017 - Ocrevus (ocrelizumab) is a humanized monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal nerve cell damage. Ocrevus is indicated as a treatment for both relapsing (RMS) and primary progressive (PPMS) forms of multiple sclerosis.

Dupixent
Mar 28, 2017 - Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis.

Zejula
Mar 28, 2017 - Zejula (niraparib) is an oral, poly ADP-ribose polymerase (PARP) inhibitor for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Symproic
Mar 28, 2017 - Symproic (naldemedine) is a peripherally-acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation.

Bavencio
Mar 24, 2017 - Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC).

Xadago
Mar 22, 2017 - Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

Kisqali
Mar 13, 2017 - Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor indicated for the treatment of postmenopausal women with HR+/HER2- metastatic breast cancer.

Siliq
Mar 2, 2017 - Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.

Qtern
Feb 28, 2017 - Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes.

Trulance
Jan 25, 2017 - Trulance (plecanatide) is a uroguanylin analog for the treatment of chronic idiopathic constipation.

Rhofade
Jan 23, 2017 - Rhofade (oxymetazoline hydrochloride) cream is a topical vasoconstrictor for the treatment of facial erythema associated with rosacea.

Browse additions by year: